Boehringer Ingelheim Vetmedica, Inc. Expands Production Facility

St. Joseph, MO, July 27, 2011 — Boehringer Ingelheim Vetmedica, Inc. (BIVI) has a strong foundation of innovative biological and pharmaceutical research and development, manufacturing and technical service. And, the company takes pride in keeping those service operations close at hand in facilities that are owned and operated in the United States by Boehringer Ingelheim Vetmedica, Inc.

In 2009, Boehringer Ingelheim Vetmedica, Inc. significantly increased the size of its animal health division with the addition of several cattle product lines and substantial manufacturing assets in Fort Dodge, IA. This was done through the acquisition of selected assets that were formerly part of Fort Dodge Animal Health. And, this year BIVI is taking the final step to integrate all of those new products into its production chain.

“Boehringer Ingelheim Vetmedica, Inc. is expanding its state-of-the-art biological GMP manufacturing facility in St. Joseph, MO., to accommodate the significant global increase in demand for animal health products,” says Colin Meyers, Executive Director of U.S. Cattle Business and Process Excellence, Boehringer Ingelheim Vetmedica, Inc. “We are excited because, with this expansion, BIVI is increasing the size of the plant by more than 50 percent.”

Upon completion of the expansion to the facility, Boehringer Ingelheim Vetmedica, Inc. will be producing several more cattle vaccine product lines at the St. Joseph, MO, facility. This will move products including Presponse®, TrichGuard®, TriVib®, Triangle®, Pyramid®, Prism™ and EnterVene™ by the end of 2011. In fact, the antigen production capacity will be increasing by 80 percent, with 50 percent going to the manufacture of cattle biological products.

Additional expansion will increase capacity in several other areas:

• Twenty percent in growth-media preparation

• One hundred percent in antigen blending

• Twenty percent in final-product filling.

“Our main goal with this expansion is to continue to provide a consistent supply of high-quality products to our customers,” Meyers says. “With our new, extensive portfolio of products for the beef and dairy businesses, we are excited about our abilities to better serve those markets.”

Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, MO), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, CT, and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, Mo.), is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, Conn., and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

For Boehringer Ingelheim — and its employees — carrying a good share of social responsibility is an important component in its business culture. Both global commitments in social projects and properly caring for all its employees are included. Respect, equal opportunity, and the balance of career and family life form the basis for mutual cooperation. And, environmental protection and sustainability are always the main focus during any of Boehringer Ingelheim’s undertakings.

In 2010, Boehringer Ingelheim posted net sales of approximately $16.7 billion (about 12.6 billion euro) while spending almost 24 percent of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit us.boehringer-ingelheim.com and follow us on Twitter at twitter.com/boehringerus.

For more information, please visit: www.bi-vetmedica.com.

Sponsored Introduction Continue on to (or wait seconds) ×